This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.
Get full access to this article
View all access options for this article.
References
1.
Blume-PeytaviU, AtkinS, ShapiroJ, ; Skin Academy. European consensus on the evaluation of women presenting with excessive hair growth. Eur J Dermtaol. 2009;19(6): 597–602.
2.
Escobar-MorrealeHF, CarminaE, DewaillyD, Epidemiology, diagnosis and management of hirsutism: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society [published correction appears in Hum Reprod Update. 2013;19(2):207]. Hum Reprod Update. 2012;18(2):146–170.
3.
MartinKA, ChangRJ, EhrmannDA, Evaluation and treatment of hirsutism in premenopausal women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(4):1105–1120.
4.
ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 108: Polycycstic ovary syndrome. Obstet Gynecol. 2009;114(4):936–949.
5.
SwigloBA, CosmaM, FlynnDN, Clinical review: Antiandrogens for the treatment of hirsutism: A systematic review and meta-analyses of randomized controlled trials. J Clin Endocrinol Metab. 2008;93(4):1153–1160.
6.
ParadisiR, VenturoliS.Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period. Eur J Endocrinol. 2010;163(1):139–147.
7.
MoghettiP, TosiF, TostiA, Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000;85(1):89–94.
8.
CalafJ, LópezE, MilletA, ; Spanish Working Group for Hirsutism. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: A 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab. 2007;92(9):3446–3452.
9.
IbáñezL, López-BermejoA, DíazM, EnríquezG, Del RíoL, De ZegherF.Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: Increasing efficacy and persistent safety over 30 months. Gynecol Endocrinol. 2010;26(12):869–873.
10.
IbáñezL, López-BermejoA, del RioL, EnríquezG, VallsC, de ZegherF.Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. J Clin Endocrinol Metab. 2007;92(5):1710–1714.
11.
IbáñezL, DíazM, SebastianiG, Treatment of androgen excess in adolescent girls: Ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin. J Clin Endocrinol Metab. 2011;96(11):3361–3366.
12.
Castelo-BrancoC, MoyanoD, GómezO, BalaschJ.Long-term safety and tolerability of flutamide for the treatment of hirsutism. Fertil Steril. 2009;91(4):1183–1188.
13.
Castelo-BrancoC, Del PinoM.Hepatotoxicity during low-dose flutamide treatment for hirsutism. Gynecol Endocrinol. 2009;25(7):419–422.
14.
BrahmJ, BrahmM, SegoviaR, Acute and fulminant hepatitis induced by flutamide: Case series report and review of the literature. Ann Hepatol. 2011;10(1):93–98.
15.
DikensoyE, BalatO, PenceS, AkcaliC, CicekH.The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. Arch Gynecol Obstet. 2009;279(3):321–327.
